posted on 2021-06-16, 21:55authored byNiklas Rutsch, Chester E. Chamberlain, Wesley Dixon, Lauren Spector, Lisa R. Letourneau-Freiberg, Wint W. Lwin, Louis H. Philipson, Alexander Zarbock, Karline Saintus, Juehu Wang, Michael S. German, Mark S. Anderson, Clifford A. Lowell
<b>OBJECTIVE: </b>Multiple genome-wide
association studies (GWAS) have identified a strong genetic linkage between the
<i>SKAP2</i> locus and type 1 diabetes (T1D) but how this leads to disease
remains obscure. Here, we characterized the functional consequence of a novel <i>SKAP2</i>
coding mutation in a T1D patient to gain further insight into how this impacts immune
tolerance.
<p><b> </b></p>
<p><b>RESEARCH DESIGN AND METHODS: </b>We identified a 24-year-old individual with T1D and other
autoimmune and inflammatory conditions. The proband and first-degree relatives
were recruited for whole exome sequencing. Functional studies of the protein
variant were performed using a cell line and primary myeloid immune cells
collected from family members.</p>
<p><b> </b></p>
<p><b>RESULTS: </b>Sequencing identified a <i>de novo</i> <i>SKAP2</i> variant (c.457G>A, p.Gly153Arg) in the proband. Assays using monocyte-derived
macrophages from the individual revealed enhanced activity of integrin pathways
and a migratory phenotype in the absence of chemokine stimulation, consistent
with SKAP2 p.Gly153Arg being constitutively active. The p.Gly153Arg variant,
located in the well-conserved lipid-binding loop, induced similar phenotypes
when expressed in a human macrophage cell line. SKAP2 p.Gly153Arg is a gain-of-function,
pathogenic mutation that disrupts myeloid immune cell function, likely resulting
in a break in immune tolerance and T1D.</p>
<p><b> </b></p>
<p><b>CONCLUSIONS: </b>SKAP2 plays a key role
in myeloid cell activation and migration. This particular mutation in a patient
with T1D and multiple autoimmunity implicates a role for activating <i>SKAP2</i>
variants in autoimmune T1D. <br>
</p>
Funding
This work was supported by the Leona M. and Harry B. Helmsley Charitable Trust (G-2018PG-T1D018, G-2003-04376), the Larry L. Hillblom Foundation (2014-D-004-NET), the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (R01 DK104942, P30 DK020595), UCSF Parnassus Flow Core RRID:SCR_018206, DRC Center Grant NIH P30 DK063720, NIH S10 1S10OD021822-01 and a private donor. Alexander Zarbock was supported by the German research foundation (ZA428/11-1; ZA428/18-1; INST 211/604-1).